Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Nindo B. Punturi; Sinem Seker; Vaishnavi Devarakonda; Aloran Mazumder; Rashi Kalra; Ching Hui Chen; Shunqiang Li; Tina Primeau; Matthew J. Ellis; Shyam M. Kavuri; Svasti Haricharan

doi:10.1038/s41467-021-23271-0

Nature Communications (May 2021)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Nindo B. Punturi,
Sinem Seker,
Vaishnavi Devarakonda,
Aloran Mazumder,
Rashi Kalra,
Ching Hui Chen,
Shunqiang Li,
Tina Primeau,
Matthew J. Ellis,
Shyam M. Kavuri,
Svasti Haricharan

Affiliations

Nindo B. Punturi: Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute
Sinem Seker: Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute
Vaishnavi Devarakonda: Lester and Sue Smith Breast Center, Baylor College of Medicine
Aloran Mazumder: Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute
Rashi Kalra: Lester and Sue Smith Breast Center, Baylor College of Medicine
Ching Hui Chen: Lester and Sue Smith Breast Center, Baylor College of Medicine
Shunqiang Li: Department of Medicine, Washington University in St. Louis
Tina Primeau: Department of Medicine, Washington University in St. Louis
Matthew J. Ellis: Lester and Sue Smith Breast Center, Baylor College of Medicine
Shyam M. Kavuri: Lester and Sue Smith Breast Center, Baylor College of Medicine
Svasti Haricharan: Tumor Microenvironment and Cancer Immunology, Sanford Burnham Prebys Medical Discovery Institute

DOI: https://doi.org/10.1038/s41467-021-23271-0
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Resistance to endocrine treatment in ER+/HER2- breast cancer patients remains a significant clinical problem. Here, the authors demonstrate that loss of the MutL mismatch repair complex can serve as a first-in-class predictive biomarker for combinatorial inhibition of HER2 to overcome the emergence of endocrine treatment resistance.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal